Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic

Lignende værker

• Using Model‐Based “Learn and Confirm” to Reveal the Pharmacokinetics‐Pharmacodynamics Relationship of Pembrolizumab in the KEYNOTE‐001 Trial
  af: Elassaiss‐Schaap, J, et al.
  Udgivet: (2016)
• Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
  af: Hamid, O, et al.
  Udgivet: (2019)
• Keynote-158 study, FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancer
  af: Borcoman, Edith, et al.
  Udgivet: (2020)
• Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006
  af: Hamid, Omid, et al.
  Udgivet: (2018)
• Two new indications for pembrolizumab have been approved in Russia
  af: article Editorial
  Udgivet: (2020-11-01)